Ryan Scott

Megan Kruse, MD, discusses the evolving treatment landscape in HR-positive, HER2-negative breast cancer, how the approval of fam-trastuzumab deruxtecan-nxki has affected sequencing choices in HER2-positive disease, and the importance of addressing racial disparities in breast cancer care.

Bridget A. Oppong, MD, discussed the importance of recognizing and addressing gaps in outcomes between patients with breast cancer in different racial groups. She also addressed the need for better advocacy for Black patients and advocated for improved screening guidelines to close the gap in racial disparities in breast cancer care.

Immunotherapy and targeted therapy combinations containing BRAF and MEK inhibitors have carved out roles in different settings of melanoma, which has given clinicians different options for treatment sequencing.

Stacey A. Cohen, MD, discusses the results of real-world analysis of patients with resected stage I-III colorectal cancer, how circulating tumor DNA status correlated with recurrence rates, and how these real-world data compared with previous observational studies.

Rana R. McKay, MD, discusses the evolution of frontline treatment options for metastatic RCC, and the key clinical trials that have shifted the treatment paradigms in metastatic castration-resistant prostate cancer, nonmetastatic castration-resistant prostate cancer, and advanced prostate cancer.

Although the exact role of minimal residual disease in patients with acute myeloid leukemia requires further definition, MRD status could help provide a clearer pathway for treatment decisions in this patient population.

R. Lor Randall, MD, FACS, discusses the poor prognosis associated with recurrent pulmonary osteosarcoma, the data from the AOST1421 trial of dinutuxumab plus granulocyte-macrophage colony-stimulating factor, and the need for expanded treatment options in osteosarcoma.

Jonathon B. Cohen MD, MS, discusses the management of chronic lymphocytic leukemia with BTK inhibitors, updates in the treatment of acute myeloid leukemia, and how CAR T-cell therapy could improve patient outcomes in diffuse large B-cell lymphoma and mantle cell lymphoma.

Jeff Yorio, MD, discussed the decision-making process for treating patients with BRAF-mutant melanoma, the use of immunotherapy in melanoma, and the management of cutaneous squamous cell carcinoma and basal cell carcinoma.

González-Martín discusses the updated long-term efficacy and safety data from the PRIMA study, the importance of utilizing PARP inhibitors in patients with homologous recombination–deficient tumors, and the benefit observed with niraparib in those with homologous recombination–proficient tumors.

R. Lor Randall, MD, FACS, discusses how disparities may lead to worse outcomes for patients diagnosed with head and neck cutaneous soft tissue sarcomas.

Single-agent dostarlimab-gxly produced progression-free survival and overall survival benefits in patients with advanced or recurrent mismatch repair–deficient/microsatellite instability–high endometrial cancer.

Jeanny B. Aragon-Ching, MD, FACP, discusses the results of the subgroup analysis in patients with urothelial carcinoma who received frontline avelumab maintenance for at least 12 months on the phase 3 JAVELIN Bladder 100 trial.

Gilteritinib, in combination with induction and consolidation chemotherapy, generated responses in patients with newly diagnosed acute myeloid leukemia, including those with FLT3 mutations, according to data from a phase 1 trial.

Sebastian C. Schmid, MD, discusses the results of the RACE IT trial, what the data mean for patients with locally advanced urothelial carcinoma, and the next steps for researching neoadjuvant radioimmunotherapy in this patient population.

Single-agent neratinib produced robust responses in patients with metastatic or recurrent HER2-mutated cervical cancer, according to updated data from phase 2 SUMMIT basket trial.

Melissa L. Johnson, MD, expands on the updated data from the POSEIDEN trial, the rationale for investigating the combination, and what these results mean for the treatment of metastatic non–small cell lung cancer.

Fam-trastuzumab deruxtecan-nxki preserved quality of life vs physicians choice of treatment in patients with advanced, hormone receptor–positive/HER2-low metastatic breast cancer.

Response to pembrolizumab monotherapy was observed regardless of prior response to chemotherapy in patients with advanced urothelial cancer.

Loncastuximab tesirine-lpyl combined with rituximab demonstrated encouraging antitumor activity and a feasible safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.

The combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelial carcinoma.

Sunvozertinib provided beneficial antitumor activity when used as a second- or later-line treatment in patients with non­­­–small cell lung cancer harboring EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy.

Nageshwara Arvind Dasari, MD, discusses the results of the phase 3 FRESCO-2 trial of fruquintinib in patients with refractory metastatic colorectal cancer, the significance of the data for the treatment paradigm, and the potential next steps for examining the agent in this disease.

The addition of AZD4635 to durvalumab or oleclumab did not elicit significant responses in heavily pretreated patients with metastatic castration-resistant prostate cancer.

TAC01-HER2 demonstrated early signals of clinical activity with a tolerable safety profile in patients with HER2-overexpressed solid tumors.

Immunotherapy-based combinations elicited higher complete response rates compared with VEGF-targeted therapy when used as first-line treatment in patients with metastatic renal cell carcinoma.

Pembrolizumab plus axitinib produced promising responses in patients with papillary or chromophobe metastatic renal cell carcinoma.

Srdan Verstovsek, MD, PhD, discusses the clinical implications of the FDA approval of pemigatinib, the results of the FIGHT-203 trial, and the need to conduct chromosomal analysis for patients with myeloid/lymphoid neoplasms.

R. Lor Randall, MD, FACS, discusses the findings from a subset analysis of the PARITY trial on the timing of neoadjuvant chemotherapy in patients with lower-extremity sarcomas.

Fixed-duration bendamustine plus rituximab was effective in patients with previously untreated Waldenström macroglobulinemia, regardless of MYD88L265P mutation status, but the presence of the CXCR4WHIM mutation may be associated with resistance to the combination.